<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:chebi fb="3" ids="44915">Propofol</z:chebi> has been demonstrated to ameliorate cerebral ischemic injury and attenuate changes in multiple links of molecular reaction included in the paths to <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="1" pm="."><plain>The experiment was aimed to evaluate whether <z:chebi fb="3" ids="44915">propofol</z:chebi> neuroprotection was mediated through the ability to regulate pathologic time-course of <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: The effect of <z:chebi fb="3" ids="44915">propofol</z:chebi> given at a series of time points during <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-reperfusion period was determined using an intraluminal middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> model in rats </plain></SENT>
<SENT sid="3" pm="."><plain>The morphological changes of <z:mpath ids='MPATH_3'>apoptosis</z:mpath> under different duration of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> were detected by terminal deoxynucleotidyl transferase (TdT)-mediated <z:chebi fb="0" ids="17625">dUTP</z:chebi>-<z:chebi fb="1" ids="15956">biotin</z:chebi> in situ nick labeling staining, and the effect of <z:chebi fb="3" ids="44915">propofol</z:chebi> on <z:mpath ids='MPATH_3'>apoptosis</z:mpath> was observed </plain></SENT>
<SENT sid="4" pm="."><plain>The expression of anti-apoptotic protein bcl-2 in post-<z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> neurons and the influence of <z:chebi fb="3" ids="44915">propofol</z:chebi> was analyzed by immunochemistry staining </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: <z:chebi fb="3" ids="44915">Propofol</z:chebi> attenuated neurological deficit, reduced <z:mpath ids='MPATH_124'>infarct</z:mpath> volumes, when given prior the <z:hpo ids='HP_0003674'>onset</z:hpo> of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, during <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> or 3 h after reperfusion </plain></SENT>
<SENT sid="6" pm="."><plain><z:mpath ids='MPATH_3'>Apoptosis</z:mpath> obviously appeared at 6 h post-reperfusion preceded by 90 min <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, rose to the maximum value at 24 h post-reperfusion and gradually diminished after 3 days reperfusion </plain></SENT>
<SENT sid="7" pm="."><plain><z:chebi fb="3" ids="44915">Propofol</z:chebi> inhibited apoptotic morphological changes between 6 h and 3 days post-reperfusion </plain></SENT>
<SENT sid="8" pm="."><plain><z:chebi fb="3" ids="44915">Propofol</z:chebi> enhanced the expression of anti-apoptotic protein bcl-2 in post-reperfusion neurons </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: The pathologic outcome of focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo>-reperfusion injury was displayed by co-existence of <z:mpath ids='MPATH_3'>apoptosis</z:mpath> and <z:mp ids='MP_0001651'>necrosis</z:mp> </plain></SENT>
<SENT sid="10" pm="."><plain>A short duration of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> induced <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="11" pm="."><plain>The therapeutic window for <z:chebi fb="3" ids="44915">propofol</z:chebi> initiated before the <z:hpo ids='HP_0003674'>onset</z:hpo> of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> and lasted until early stage of reperfusion </plain></SENT>
<SENT sid="12" pm="."><plain>The neuroprotection of <z:chebi fb="3" ids="44915">propofol</z:chebi> might be attributed to the inhibition of <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
</text></document>